A phase I study of α-galactosylceramide (KRN7000)-pulsed dendritic cells in patients with advanced and recurrent non-small cell lung cancer

Clinical Cancer Research

Volumn 11, Issue 5, 2005, Pages 1910-1917

  Ishikawa, Aki ^a   Motohashi, Shinichiro ^a   Ishikawa, Eiichi ^a   Fuchida, Hiroki ^a   Higashino, Kazuko ^a   Otsuji, Mizuto ^a   Iizasa, Toshihiko ^a   Nakayama, Toshinori ^a   Taniguchi, Masaru ^b   Fujisawa, Takehiko ^a  

^a CHIBA UNIVERSITY   (Japan)

^b RIKEN YOKOHAMA INSTITUTE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

1 O (ALPHA GALACTOPYRANOSYL) 2 HEXACOSANOYLAMINO 1,3,4 OCTADECANETRIOL;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BLOOD; CANCER PATIENT; CANCER RECURRENCE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYSTITIS; DENDRITIC CELL; DOSE RESPONSE; DRUG DOSE REGIMEN; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEASIBILITY STUDY; FEMALE; HEADACHE; HOT FLUSH; HUMAN; HYPERBILIRUBINEMIA; HYPERKALEMIA; LUNG NON SMALL CELL CANCER; MALE; NATURAL KILLER CELL; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; QUALITY OF LIFE; SAMPLE SIZE; SIDE EFFECT; STATISTICAL SIGNIFICANCE; TREATMENT OUTCOME;

AGED; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; CELL CULTURE TECHNIQUES; CELL PROLIFERATION; DENDRITIC CELLS; FEMALE; GALACTOSYLCERAMIDES; HUMANS; IMMUNOTHERAPY; INFUSIONS, INTRAVENOUS; KILLER CELLS, NATURAL; LUNG NEOPLASMS; MALE; MIDDLE AGED; TREATMENT OUTCOME;

EID: 20144388064     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-04-1453     Document Type: Article

References (45)

1. Taniguchi M, Harada M, Kojo S, Nakayama T, Wakao H. The regulatory role of Vα14 NKT cells in innate and acquired immune response. Annu Rev Immunol 2003;21:483-513.
2. Godfrey DI, MacDonald HR, Kronenberg M, Smyth MJ, Van Kaer L. NKT cells: what's in a name? Nat Rev Immunol 2004;4:231-7.
3. Kawano T, Cui J, Koezuka Y, et al. CD1d-restricted and TCR-mediated activation of Vα14 NKT cells by glycosylceramides. Science 1997;278:1626-9.
4. Brossay L, Chioda M, Burdin N, et al. CD1d-mediated recognition of an α-galactosylceramide by natural killer T cells is highly conserved through mammalian evolution. J Exp Med 1998;188:1521-8.
5. Spada FM, Koezuka Y, Porcelli SA. CD1d-restricted recognition of synthetic glycolipid antigens by human natural killer T cells. J Exp Med 1998;188:1529-34.
6. Kawano T, Tanaka Y, Shimizu E, et al. A novel recognition motif of human NKT antigen receptor for a glycolipid ligand. Int Immunol 1999;11:881-7.
7. Porcelli SA, Modlin RL. The CD1 system: Antigen-presenting molecules for T cell recognition of lipids and glycolipids. Annu Rev Immunol 1999;17:297-329.
8. Kawano T, Cui J, Koezuka Y, et al. Natural killer-like nonspecific tumor cell lysis mediated by specific ligand-activated Vα14 NKT cells. Proc Natl Acad Sci U S A 1998;95:5690-3.
9. Naiki Y, Nishimura H, Kawano T, et al. Regulatory role of peritoneal NK1.1+ αβ T cells in IL-12 production during Salmonella infection. J Immunol 1999;163:2057-63.
10. Nakagawa R, Motoki K, Ueno H, et al. Treatment of hepatic metastasis of the colon26 adenocarcinoma with an α-galactosylceramide, KRN7000. Cancer Res 1998;58:1202-7.
11. Shin T, Nakayama T, Akutsu Y, et al. Inhibition of tumor metastasis by adoptive transfer of IL-12-activated Vα14 NKT cells. Int J Cancer 2001;91:523-8.
12. + NKT cells activated by α-glycosylceramide- pulsed monocyte-derived dendritic cells. J Immunol 2000;164:4458-64.
13. Wilson SB, Delovitch TL. JANUS-like role of regulatory iNKT cells in autoimmune disease and tumor immunity. Nat Rev Immunol 2003;3:211-22.
14. Carnaud C, Lee D, Donnars O, et al. Cutting edge: Cross-talk between cells of the innate immune system: NKT cells rapidly activate NK cells. J Immunol 1999;163:4647-50.
15. Hayakawa Y, Takeda K, Yagita H, et al. Critical contribution of IFN-γ and NK cells, but not perforin-mediated cytotoxicity, to antimetastatic effect of α-galactosylceramide. Eur J Immunol 2001;31:1720-7.
16. Nishimura T, Kitamura H, Iwakabe K, et al. The interface between innate and acquired immunity: glycolipid antigen presentation by CD1d-expressing dendritic cells to NKT cells induces the differentiation of antigen-specific cytotoxic T lymphocytes. Int Immunol 2000;12:987-94.
17. Fujii S, Shimizu K, Kronenberg M, Steinman RM. Prolonged IFN-γ producing NKT response induced with α-galactosylceramide-loaded DCs. Nat Immunol 2002;3:867-74.
18. Toura I, Kawano T, Akutsu Y, et al. Cutting edge: Inhibition of experimental tumor metastasis by dendritic cells pulsed with α-galactosylceramide. J Immunol 1999;163:2387-91.
19. Akutsu Y, Nakayama T, Harada M, et al. Expansion of lung Vα14 NKT cells by administration of α-galactosylceramide-pulsed dendritic cells. Jpn J Cancer Res 2002;93:397-403.
20. Motohashi S, Kobayashi S, Ito T, et al. Preserved IFN-γ production of circulating Vα24 NKT cells in primary lung cancer patients. Int J Cancer 2002;102:159-65.
21. Godfrey DI, Hammond KJ, Poulton LD, Smyth MJ, Baxter AG. NKT cells: facts, functions and fallacies. Immunol Today 2000;21:573-83.
22. Kronenberg M, Gapin L. The unconventional lifestyle of NKT cells. Nat Rev Immunol 2002;2:557-68.
23. Tahir SM, Cheng O, Shaulov A, et al. Loss of IFN-γ production by invariant NK T cells in advanced cancer. J Immunol 2001;167:4046-50.
24. Sumida T, Sakamoto A, Murata H, et al. Selective reduction of T cells bearing invariant Vα24JαQ antigen receptor in patients with systemic sclerosis. J Exp Med 1995;182:1163-8.
25. + NKT cells during HIV type 1 infection. J Immunol 2002;168:1490-5.
26. + NKT cells derived from multiple sclerosis in remission. Int Immunol 2003;15:279-88.
27. Kobayashi S, Kaneko Y, Seino K, et al. Impaired IFN-γ production of Vα24 NKT cells in non-remitting sarcoidosis. Int Immunol 2004;16:215-22.
28. Giaccone G, Punt CJ, Ando Y, et al. A phase I study of the natural killer T-cell ligand α-galactosylceramide (KRN7000) in patients with solid tumors. Clin Cancer Res 2002;8:3702-9.
29. Osman Y, Kawamura T, Naito T, et al. Activation of hepatic NKT cells and subsequent liver injury following administration of α-galactosylceramide. Eur J Immunol 2000;30:1919-28.
30. Kaneko Y, Harada M, Kawano T, et al. Augmentation of Vα14 NKT cell-mediated cytotoxicity by interleukin 4 in an autocrine mechanism resulting in the development of concanavalin A-induced hepatitis. J Exp Med 2000;191:105-14.
31. + T cells preferentially accumulate in human liver. Eur J Immunol 1999;29:2406-13.
32. Fong L, Engleman EG. Dendritic cells in cancer immunotherapy. Annu Rev Immunol 2000;18:245-73.
33. Thurner B, Haendle I, Roder C, et al. Vaccination with Mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma. J Exp Med 1999;190:1669-78.
34. Stift A, Friedl J, Dubsky P, et al. Dendritic cell-based vaccination in solid cancer. J Clin Oncol 2003;21:135-42.
35. Butterfield LH, Ribas A, Dissette VB, et al. Determinant spreading associated with clinical response in dendritic cell-based immunotherapy for malignant melanoma. Clin Cancer Res 2003;9:998-1008.
36. Su Z, Dannull J, Heiser A, et al. Immunological and clinical responses in metastatic renal cancer patients vaccinated with tumor RNA-transfected dendritic cells. Cancer Res 2003;63:2127-33.
37. + T cells by non-major histocompatibility complex-encoded class I-like molecules expressed on bone marrow-derived cells. Proc Natl Acad Sci U S A 1995;92:1200-4.
38. Morse MA, Coleman RE, Akabani G, et al. Migration of human dendritic cells after injection in patients with metastatic malignancies. Cancer Res 1999;59:56-8.
39. Mountain CF. Revisions in the International System for Staging Lung Cancer. Chest 1997;111:1710-7.
40. Stenbygaard LE, Sorensen JB, Olsen JE. Metastatic pattern in adenocarcinoma of the lung. An autopsy study from a cohort of 137 consecutive patients with complete resection. J Thorac Cardiovasc Surg 1995;110:1130-5.
41. Pairolero PC, Williams DE, Bergstralh EJ, et al. Postsurgical stage I bronchogenic carcinoma: morbid implications of recurrent disease. Ann Thorac Surg 1984;38:331-8.
42. Nieda M, Okai M, Tazbirkova A, et al. Therapeutic activation of Vα24 + Vβ11+ NKT cells in human subjects results in highly coordinated secondary activation of acquired and innate immunity. Blood 2004;103:383-9.
43. Wilson MT, Johansson C, Olivares-Villagomez D, et al. The response of natural killer T cells to glycolipid antigens is characterized by surface receptor down-modulation and expansion. Proc Natl Acad Sci U S A 2003;100:10913-8.
44. Harada M, Seino K, Wakao H, et al. Down-regulation of the invariant Vα14 antigen receptor in NKT cells upon activation. Int Immunol 2004;16:241-7.
45. Crowe NY, Uldrich AP, Kyparissoudis K, et al. Glycolipid antigen drives rapid expansion and sustained cytokine production by NK T cells. J Immunol 2003;171:4020-7.